Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun;19(6):2745-2749.
doi: 10.1002/alz.13022. Epub 2023 Mar 16.

Prospective evaluation of plasma phosphorylated tau in a real-life memory clinic in Thailand

Poosanu Thanapornsangsuth  1   2   3 , Kittithatch Booncharoen  2   3   4 , Watayuth Luechaipanit  1 , Thirawat Supharatpariyakorn  1 , Yuthachai Sarutikriangkri  3   4 , Suchart Tangnimitchok  5 , Yuttachai Likitjaroen  2   3   4 , Chanan Sukprakun  6 , Supatporn Tepmongkol  6 , Thiravat Hemachudha  1   2
Affiliations

Prospective evaluation of plasma phosphorylated tau in a real-life memory clinic in Thailand

Poosanu Thanapornsangsuth et al. Alzheimers Dement. 2023 Jun.

Abstract

Introduction: Despite the substantial accuracy of plasma p-tau in diagnosing Alzheimer's disease (AD) in research cohorts, data on real-life memory clinic patients are lacking.

Methods: Memory clinic patients at their early symptomatic stages were prospectively enrolled to undergo routine clinical assessment, plasma p-tau181 quantification (Simoa), amyloid and tau-positron emission tomography (PET). The diagnostic performance of plasma p-tau181, neurocognitive specialists, and regional tau-PET were compared head-to-head using amyloid-PET as the reference standard.

Results: Plasma p-tau181 has the area under the curve (AUC), sensitivity, specificity, and accuracy of 0.84 (95% confidence interval [CI] 0.73-0.94), 0.80 (95% CI 0.64-0.90), 0.75 (95% CI 0.51-0.90), and 0.78 (95% CI 0.65-0.88) for detecting amyloid-PET positivity in early symptomatic patients, respectively. The AUC of clinical diagnosis and tau-PET were 0.70 (95% CI 0.56-0.85) and 0.88 (95% CI 0.79-0.97), respectively.

Discussion: Plasma p-tau181 also performed well in real-life memory clinic settings and its role in clinical practice is supported.

Keywords: blood-based biomarkers; clinical diagnosis; memory clinic; plasma phosphorylated tau; tau-positron emission tomography.

PubMed Disclaimer

References

REFERENCES

    1. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology. 2020;19(5):422-433.
    1. Lantero Rodriguez J, Karikari TK, Suárez-Calvet M, et al. Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol. 2020;140(3):267-278.
    1. Janelidze S, Palmqvist S, Leuzy A, et al. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau. Alzheimers Dement. 2022;18(2):283-293.
    1. Keshavan A, Pannee J, Karikari TK, et al. Population-based blood screening for preclinical Alzheimer's disease in a British birth cohort at age 70. Brain. 2021;144(2):434-449.
    1. Ashton NJ, Pascoal TA, Karikari TK, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology. Acta Neuropathol. 2021;141(5):709-724.

Publication types

LinkOut - more resources